Gene expression in humans with diabetes and prediabetes: What have we learned about diabetes pathophysiology?

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 7, Issue 4, 2004, Pages 383-390

  Patti, Mary Elizabeth ^a,b  

^a JOSLIN DIABETES CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Diabetes mellitus; Gene expression profiling; Insulin resistance genetics; Muscle; Oxidative phosphorylation; Skeletal metabolism; Transcription factors physiology; Type ll genetics

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1; PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME-PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA COACTIVATOR-1;

AEROBIC METABOLISM; CELL FUNCTION; DIABETES MELLITUS; ENVIRONMENTAL FACTOR; FAMILY HISTORY; GENE ACTIVITY; GENE EXPRESSION; GENOME ANALYSIS; GENOMICS; GLUCOSE TOLERANCE; HEREDITY; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; MITOCHONDRION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PHENOTYPE; PROTEIN FUNCTION; REVIEW; RISK ASSESSMENT; SKELETAL MUSCLE; TRANSCRIPTION REGULATION; ENERGY METABOLISM; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; METABOLISM; PANCREAS ISLET; PHYSIOLOGY;

DIABETES MELLITUS, TYPE 2; ENERGY METABOLISM; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INSULIN RESISTANCE; ISLETS OF LANGERHANS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PREDIABETIC STATE; TRANSCRIPTION FACTORS;

EID: 9144273505     PISSN: 13631950     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mco.0000134359.23288.72     Document Type: Review

References (59)

1. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States. US Department of Health and Human Servies, Centers for Disease Control and Prevention; 2003.
2. Mokdad AH, Ford ES, Bowman BA, et al. Diabetes trends in the US: 1990-1998. Diabetes Care 2000; 23:1278-1283.
3. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 2002; 287:356-359.
4. Ninomiya JK, L'Italien G, Criqui MH, et al. Association of the metabolic syndrome with history of myocardial infarction and stroke in the third national health and nutrition examination survey. Cirulation 2004; 109:42-46.
5. Eriksson J, Franssila-Kallunki A, Ekstrand A, et al. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med 1989; 321:337-343.
6. Martin BC, Warram JH, Krolewski AS, et al. Role of glucose and insulin resistance in development of type Il diabetes mellitus: results of a 25-year follow-up study. Lancet 1992; 340:925-929.
7. Cusi K, Maezono K, Osman A, et al. Insulin resistance differentially affects the P1 3-kinase-and MAP kinase-mediated signaling in human muscle. J Clin Invest 2000; 105:311-320.
8. Ducluzeau PH, Perretti N, Laville M, et al. Regulation by insulin of gene expression in human skeletal muscle and adipose tissue. Evidence for specific defects in type 2 diabetes. Diabetes 2001; 50:1134-1142.
9. Jacob S, Machann J, Rett K, et al. Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects. Diabetes 1999; 48:1113-1119.
10. Williams RS, Salmons S, Newsholme EA, et al. Regulation of nuclear and mitochondrial gene expression by contractile activity in skeletal muscle. J Biol Chem 1986; 261:376-380.
11. Brüning JC, Michael MD, Winnay JN, et al. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol Cell 1998; 2:559-569.
12. Shuldiner AR, Yang R, Gong DW. Resistin, obesity and insulin resistance - the emerging role of the adipocyte as an endocrine organ. N Engl J Med 2001; 345:1345-1346.
13. Yakar S, Liu JL, Fernandez AM, et al. Liver-specific igf-1 gene deletion leads to muscle insulin insensitivity. Diabetes 2001 ; 50:1110-1118.
14. Kubota N, Tobe K, Terauchi Y, et al. Disruption of insulin receptor substrate 2 causes type 2 diabetes because of liver insulin resistance and lack of compensatory b-cell hyperplasia. Diabetes 2000; 49:1880-1889.
15. Brüning JC, Gautam D, Burkes DJ, et al. Role of brain insulin receptor in control of body weight and reproduction. Science 2000; 289:2122-2125.
16. Patti ME, Virkamaki A, Landaker EJ, Yki-Jarvinen H. Activation of the hexosamine pathway by glucosamine in vivo decreases insulin-stimulated Pl 3-kinase in skeletal muscle. Diabetes 1999; 48:1562-1571.
17. Yechoor VK, Patti ME, Saccone R, Kahn CR. Coordinated patterns of gene expression for substrate and energy metabolism in skeletal muscle of diabetic mice. Proc Natl Acad Sci U S A 2002; 99:10587-10592. This paper demonstrates that experimental insulin deficiency and diabetes is associated with changes in expression of multiple metabolic genes, including downregulation of electron transport genes and upregulation of lipid metabolism genes. Many of these genes were normalized by insulin treatment.
18. Lockhart DJ, Dong H, Byrne MC, et al. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol 1996; 14:1675-1680.
19. Sutcliffe JG, Foye PE, Erlander MG, et al. TOGA: an automated parsing technology for analyzing expression of nearly all genes. Proc Natl Acad Sci USA 2000; 97:1976-1981.
20. Bustin SA. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 2000; 25:169-193.
21. Kerr MK, Churchill GA. Statistical design and the analysis of gene expression microarray data. Genet Res 2001; 77:123-128.
22. Patti ME, Butte AJ, Crunkhorn S, et al. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc Natl Acad Sci U S A 2003; 100:8466-8471. This paper demonstrates that nuclear-encoded genes regulating mitochondrial metabolism and function are altered in both diabetic subjects and in insulin resistant first degree relatives of diabetics, even in the presence of normal glucose tolerance, and suggested that changes in PGC1 expression and/or function might underlie this phenotype.
23. Draghici S, Khatri P, Martins R, et al. Global functional profiling of gene expression. Genomics 2003; 81:1-7.
24. Doniger SW, Salomonis N, Dahlquist KD, et al. MAPPFinder: using gene ontology and GenMAPP to create a global gene-expression profile from microarray data. Genome Biol 2003; 4:R7. Epub ahead of print. The two papers above highlight the utility of looking for patterns of gene expression changes in groups of genes clustered by biological function (ontology) when interpreting data from large-scale microarray data.
25. Sreekumar R, Halvatsiotis P, Schimke JC, Nair KS. Gene expression profile in skeletal muscle of type 2 diabetes and the effect of insulin treatment. Diabetes 2002; 51:1913-1920. This paper showed that uncontrolled diabetes is associated with abnormal regulation of multiple genes, and that improved control of diabetes can at least partially normalize abnormalities in expression in several key metabolic pathways.
26. Mootha VK, Lindgren CM, Eriksson KF, et al. PGC-1 alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003; 34:267-273. These authors demonstrate that both impaired glucose tolerance and overt diabetes are associated with reduced expression of PGC-1-regulated oxidative phosphorylation genes in Caucasians.
27. Yang X, Pratley RE, Tokraks S, et al. Microarray profiling of skeletal muscle tissues from equally obese, non-diabetic insulin-sensitive and insulin-resistant Pima Indians. Diabetologia 2002; 45:1584-1593.
28. Scarpulla RC. Transcriptional activators and coactivators in the nuclear control of mitochondrial function in mammalian cells. Gene 2002; 286:81-89.
29. Baar K, Song Z, Semenkovich CF, et al. Skeletal muscle overexpression of nuclear respiratory factor 1 increases glucose transport capacity. FASEB J 2003; 17:1666-1673. This paper demonstrates that increasing mitochondrial capacity can influence carbohydrate metabolism in muscle.
30. Lin J, Puigserver P, Donovan J, et al. Peroxisome proliferator-activated receptor gamma coactivator 1beta (PGC-1beta), a novel PGC-1-related transcription coactivator associated with host cell factor. J Biol Chem 2002; 277:1645-1648.
31. Puigserver P, Spiegelman BM. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr Rev 2003; 24:78-90. This is a comprehensive review of the role of PGC-1 coactivator gene family in modulating transcription related to key metabolic pathways.
32. Pilegaard H, Saltin B, Neufer PD. Exercise induces transient transcriptional activation of the PGC-1 alpha gene in human skeletal muscle. J Physiol 2003; 546:851-858. Exercise training increases expression of PGC-1 and mitochondrial gene transcription, thus suggesting that PGC-1 may be an important link between exercise, improved mitochondrial function, and improved insulin sensitivity
33. Semple RK, Crowley VC, Sewter CP, et al. Expression of the thermogenic nuclear hormone receptor coaclivator PGC-1alpha is reduced in the adipose tissue of morbidly obese subjects. Int J Obes Relat Metab Disord 2004; 28:176-179. This paper demonstrates that PGC-1 expression is reduced in adipose tissue in obesity, suggesting an important role for mitochondrial function in obesity.
34. Hammarstedt A, Jansson PA, Wesslau C, et al. Reduced expression of PGC-1 and insulin-signaling molecules in adipose tissue is associated with insulin resistance. Biochem Biophys Res Commun 2003; 301:578-582.
35. Tiraby C, Tavernier G, Lefort C, et al. Acquirement of brown fat cell features by human white adipocytes. J Biol Chem 2003; 278:33370-33376.
36. Tritos NA, Mastaitis JW, Kokkotou EG, et al. Characterization of the peroxisome proliferator activated receptor coactivator 1 alpha (PGC 1alpha) expression in the murine brain. Brain Res 2003; 961:255-260.
37. Pratley RE, Thompson DB, Prochazka M, et al. An autosomal genomic scan for loci linked to prediabetic phenotypes in Pima Indians. J Clin Invest 1998; 101:1757-1764.
38. Stone S, Abkevich V, Hunt SC, et al. A major predisposition locus for severe obesity, at 4p15-p14. Am J Hum Genet 2002; 70:1459-1468.
39. Arya R, Blangero J, Almasy L, et al. Evidence of a novel quantitative-trait locus for obesity on chromosome 4p in Mexican Americans. Am J Hum Genet 2004; 74:272-282.
40. Esterbauer H, Oberkofler H, Linnemayr V, et al. Peroxisome proliferator-activated receptor-gamma coactivator-1 gene locus: associations with obesity indices in middle-aged women. Diabetes 2002; 51:1281-1286.
41. Ek J, Andersen G, Urhammer SA, et al. Mutation analysis of peroxisome proliferator-activated receptor-gamma coactivator-1 (PGC-1) and relationships of identified amino acid polymorphisms to type II diabetes mellitus. Diabetologia 2001; 44:2220-2226.
42. Hara K, Tobe K, Okada T, et al. A genetic variation in the PGC-1 gene and insulin resistance. Diabetologia 2002; 45:740-743.
43. Muller YL, Bogardus C, Pedersen O, Baier L. A Gly482Ser missense mutation in the peroxisome proliferator-activated receptor gamma coactivator-1 is associated with altered lipid oxidation and early insulin secretion in Pima Indians. Diabetes 2003; 52:895-898. This paper suggests that mutations in PGC1 may contribute to reduced lipid oxidation, thus contributing to insulin resistance and insulin secretory dysfunction.
44. Altshuler D, Hirschhorn JN, Klannemark M, et al. The common PPARgamma Pro12A1a is associated with decreased risk of type 2 diabetes. Nat Genet 2000; 26:76-80.
45. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 2002; 51:2796-2803.
46. Inzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998; 338:867-872.
47. Norrbom J, Sundberg CJ, Ameln H, et al. PGC-1alpha mRNA expression is influenced by metabolic perturbation in exercising human skeletal muscle. J Appl Physiol 2004; 96:189-194.
48. Russell AP, Feilchenfeldt J, Schreiber S, et al. Endurance training in humans leads to fiber type-specific increases in levels of peroxisome proliferator-activated receptor-gamma coactivator-1 and peroxisome proliferator-activated receptor-alpha in skeletal muscle 1. Diabetes 2003; 52:2874-2881. The above 2 papers again highlight that exercise training may modulate the PGC-1-related expression phenotype and thus improve mitochondrial function and insulin resistance.
49. Kashyap S, Richardson D, Jenkinson CP, et al. Increased plasma FFA alter gene expression in human muscle in vivo [abstract]. Diabetes 2003; 52 (Suppl1):A244. This abstract suggests that short-term increases in free fatty acids can downregulate oxidative phosphorylation gene expression in parallel with induction of insulin resistance.
50. Obici S, Wang J, Chowdury R, et al. Identification of a biochemical link between energy intake and energy expenditure. J Clin Invest 2002; 109:1599-1605.
51. Larrouy D, Vidal H, Andreelli F, et al. Cloning and mRNA tissue distribution of human PPARgamma coactivator-1. Int J Obes Relat Metab Disord 1999; 23:1327-1332.
52. Kelley DE, Simoneau JA. Impaired free fatty acid utilization by skeletal muscle in non-insulin-dependent diabetes mellitus. J Clin Invest 1994; 94:2349-2356.
53. Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 2002; 32 (Suppl. 3):14-23.
54. Simoneau JA, Veerkamp JH, Turcotte LP, Kelley DE. Markers of capacity to utilize fatty acids in human skeletal muscle: relation to insulin resistance and obesity and effects of weight loss. FASEB J 1999; 13:2051-2060.
55. Kelley DE, He J, Menshikova EV, Ritov VB. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 2002; 51:2944-2950.
56. Song J, Oh JY, Sung YA, et al. Peripheral blood mitochondrial DNA content is related to insulin sensitivity in offspring of type 2 diabetic patients. Diabetes Care 2001; 24:865-869.
57. Petersen KF, Dufour S, Befroy D, et al. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 2004; 350:664-671. The authors demonstrate that ATP production is reduced even in nondiabetic first-degree relatives of diabetics, again pointing to mitochondrial dysfunction early in the course of diabetes development.
58. Petersen KF, Befroy D, Dufour S, et al. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 2003; 300:1140-1142. Mitochondrial function is reduced with aging and may contribute to age-related development of insulin resistance.
59. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344:1343-1350.